CytRx (CYTR) Jumping On Drug Candidate INNO-206 Results in Ovarian Tumor Shrinkage in Animal Trials
Tweet Send to a Friend
CytRx Corporation (NASDAQ: CYTR) is up 4% after announcing that results demonstrating that its cancer drug candidate INNO-206 caused statistically ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
